Boehringer Ingelheim regenerates Agomab

Apr 16, 2019 • James Mawson

Boehringer Ingelheim Venture Fund has participated in a $23.8m round for the antibody developer spun out of University of Turin.

Agomab Therapeutics, a Belgium-based developer of tissue regeneration technology based on research at University of Turin, has secured €21m ($23.8m) in series A funding from a consortium including pharmaceutical firm Boehringer Ingelheim.
The round was co-led by venture capital fund V-Bio Ventures and life sciences VC firm Advent France Biotechnology and included Omnes and Pontifax, while Boehringer Ingelheim invested through corporate venturing vehicle Boehringer Ingelheim Venture Fund (BIVF).
Founded in 2017, Agomab is developing antibodies for the regeneration…

LEADERSHIP SOCIETY

Informing, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.

Find out more

Can University of Kentucky researchers bring new flavours to whisky?

The University of Kentucky has formed an industry-university partnership to advance aspects such as sustainable agriculture in the whiskey distilling industry.

Make sure UK proof-of-concept funds go beyond Golden Triangle, say experts

The £40m recently allocated by the UK government to proving university research is commercially viable shouldn't just benefit Oxford, Cambridge and London say sector pundits.

Databricks cofounder launches $150m spinout fund with UC Berkeley focus

The investment fund will mostly back founders from the US university.

Events

GCV Institute: CVC Investment Programs

Jan 28 -
Jan 29, 2025
Online

Find out more All events

Events

GCV Institute: CVC Investment Programs

Mar 17 -
Mar 18, 2025
Palo Alto, CA (USA)

Find out more All events

Events

GCVI Summit 2025

Mar 18 -
Mar 20, 2025
Monterey, CA (USA)

Find out more All events

Events

GCV Institute: Landing the Value of Corporate Venturing

May 1 -
May 6, 2025
Online

Find out more All events

Events

GCV Symposium 2025

Jun 17 -
Jun 19, 2025
London (UK)

Find out more All events

About us

Global University Venturing (GUV) is where tech transfer, academic and investment experts meet to explore the latest ideas and technologies driving innovation forward. We drive the discussions and share best practices that are critical to the success of spinouts, scaleouts and innovation programmes. Our aim is to help improve the processes of bringing innovations from academia to global markets and facilitate their integration into the broader business ecosystem.